Amphastar Pharmaceuticals Reports Revenues of $55.9 Million for the Fourth Quarter Ended December 31, 2014
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/23/2026
Go back to Amphastar Pharmaceuticals Reports Revenues of $55.9 Million for the Fourth Quarter Ended December 31, 2014
March 25, 2015 7:43 AM EDT
Jefferies analyst David Steinberg reiterated a Buy rating and boosted his price target on Amphastar Pharmaceuticals (NASDAQ: AMPH) to $18.00 (from $15.00) following a narrower Q4 loss.
Steinberg commented, "AMPH Q4 EPS of -$0.03 was +0.03 ahead of our est, with higher op expenses... More
March 25, 2015 6:58 AM EDT
Piper Jaffray analyst David Amsellem reiterated an Overweight-rating and boosted his price target on Amphastar Pharmaceuticals (NASDAQ: AMPH) to $19.00 (from $16.00) following solid execution in Q4.
Amsellem commented, "Amphastar reported a 4Q14 net loss per share of ($0.03) on revenues of $56M, compared to the Street estimates of ($0.07) and... More
March 24, 2015 4:03 PM EDT
Amphastar Pharma (NASDAQ: AMPH) reported Q4 EPS of ($0.03), $0.07 better than the analyst estimate of ($0.10). Revenue for the quarter came in at $55.9 million, versus $54.9 million reported last year.
For earnings history and earnings-related data on Amphastar Pharma (AMPH) click here.
...
More
